secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERU INC. (VERU)
CIK:        0000863894
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001193125-25-115453
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Veru's enobosarm Phase 2b meets primary endpoint; 71% less lean mass loss with GLP-1
--------------------------------------------------------------------------------

- Phase 2b QUALITY study met primary endpoint: 71% relative reduction in lean mass loss with enobosarm + semaglutide vs placebo (p=0.002).
- Enobosarm 3mg dose resulted in >99% mean relative reduction in lean mass loss (p<0.001); enobosarm 6mg not more effective.
- Enobosarm + semaglutide shifted weight loss composition to fat: 90.6% fat loss vs 68% with placebo (p=0.014 for fat mass loss with 6mg).
- Physical function improved: 54.4% relative reduction in proportion with ≥10% decline in stair climb power (p=0.0049) for all enobosarm.
- Upcoming catalysts: unblinded safety data and Phase 2b extension topline data expected in Q2 2025; End of Phase 2 FDA meeting planned for Q3 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/863894/000119312525115453/0001193125-25-115453-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/863894/000119312525115453/d937042d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-115453

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer